Jack W. Callicutt
2016
In 2016, Jack W. Callicutt earned a total compensation of $503.9K as Chief Financial Officer at Galectin Therapeutics, a 18% increase compared to previous year.
Compensation breakdown
| Bonus | $54,172 |
|---|---|
| Option Awards | $140,587 |
| Salary | $260,000 |
| Other | $49,097 |
| Total | $503,856 |
Callicutt received $260K in salary, accounting for 52% of the total pay in 2016.
Callicutt also received $54.2K in bonus, $140.6K in option awards and $49.1K in other compensation.
Rankings
In 2016, Jack W. Callicutt's compensation ranked 11,137th out of 14,075 executives tracked by ExecPay. In other words, Callicutt earned more than 20.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,137 out of 14,075 | 21st |
Division Manufacturing | 4,323 out of 5,489 | 21st |
Major group Chemicals And Allied Products | 1,542 out of 1,895 | 19th |
Industry group Drugs | 1,243 out of 1,538 | 19th |
Industry Pharmaceutical Preparations | 968 out of 1,176 | 18th |
Source: SEC filing on November 7, 2017.
Callicutt's colleagues
We found two more compensation records of executives who worked with Jack W. Callicutt at Galectin Therapeutics in 2016.
News
Galectin Therapeutics CEO Joel Lewis' 2023 pay slips 1% to $964K
December 3, 2024
Galectin Therapeutics CEO Joel Lewis' 2022 pay slips 17% to $974K
October 6, 2023
Galectin Therapeutics CEO Joel Lewis' 2021 pay jumps 55% to $1.2M
October 17, 2022
Galectin Therapeutics CEO Harold Shlevin's 2019 pay falls 25% to $1.3M
October 19, 2020